Data Bridge Market Research analyses that the Neonatal Seizures Drugs Market was valued at USD 222.5 million in 2021 and is expected to reach USD 290.73 million by 2029, registering a CAGR of 3.40% during the forecast period of 2022 to 2029.
The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Due to the limited evidence available to help decide the appropriate usage of drugs for children of all ages with varied forms of epilepsy, doctors confront unique problems while treating children with epilepsy. However, progress has recently been made in understanding how antiepileptic medicines (AEDs) can be used to treat new born seizures and infantile spasms, which are seizure disorders that occur in the first year of life. The efficacy of AEDs in treating these illnesses has been disputed, and predicting the fate of these problems for each kid has been challenging, so any advancement is welcome.
Seizures in neonates are aberrant electrical discharges in the central nervous system that typically appear as stereotyped muscle activity or autonomic abnormalities. Electroencephalography confirms the diagnosis, and further testing for reasons is recommended. Treatment is determined by the underlying cause. Seizures affect up to 1.4 percent of full-term new-borns and 20% of premature infants. Seizures could be a sign of a significant neonatal condition that has to be evaluated right away. The lack of myelination and insufficient creation of dendrites and synapses in neonates prevents generalization of electrical activity, hence most neonatal seizures are focal.
Get Sample PDF of the Neonatal Seizures Drugs Market Report: - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-neonatal-seizures-drugs-market
Neonatal Seizures Drugs Market Dynamics
Drivers
- Increasing prevalence of hypoxia-ischemia
The rising prevalence of hypoxia-ischemia is anticipated to influence the neonatal seizures drugs market’s growth. The most prevalent cause of neonatal seizures is hypoxia-ischemia, which can occur before, during, or after delivery. Seizures of this nature can be severe and difficult to treat, but they usually subside after 3 to 4 days. Seizures may be less severe when new-born hypoxia is treated with therapeutic hypothermia (typically whole-body chilling), although they may recur upon rewarming.
- Rising incidences of neonatal infections
The increasing incidences of neonatal infections is expected to flourish the market's growth rate during the forecast period of 2022-2029. Seizures can occur as a result of neonatal infections including meningitis and sepsis; in these cases, seizures are usually accompanied by other symptoms and signs. In neonates, group B streptococci and gram-negative bacteria are the most common causes of infection. Seizures can also be caused by encephalitis caused by the cytomegalovirus, herpes simplex virus, rubella virus, Treponema pallidum, Toxoplasma gondii, or Zika virus.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the neonatal seizures drugs market. Additionally, rising healthcare expenditure and changing lifestyle of people will result in the expansion of neonatal seizures drugs market. Along with this, rising prevalence rate of chronic disease such as thyroid, diabetes, and kidney disease, and favourable reimbursement policies will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the neonatal seizures drugs market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of neonatal seizures drugs during the forecast period.
Global Neonatal Seizures Drugs Market Scope
The neonatal seizures drugsmarket is segmented on the basis of type, drug, and dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Tonic Seizures
- Clonic and Myoclonic Seizures
- Non-Paroxysmal Repetitive Behaviours
Drug
- Dilantin
- Phenobarbital
- Other
Dosage
- Injection
- Tablets
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Get TOC Details of the Report: - https://www.databridgemarketresearch.com/toc/?dbmr=global-neonatal-seizures-drugs-market
Neonatal Seizures Drugs Market Regional Analysis/Insights
The neonatal seizures drugs market is analysed and market size insights and trends are provided by country, type, drug, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the neonatal seizures drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the neonatal seizures drugs market because of the rising level of investment on research and development activities in this region. Additionally, the growing presence of major key players and well-established healthcare infrastructure will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region. Also, surging prevalence of kidney diseases, thyroid and liver disorders and the number of generic medications will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Neonatal Seizures Drugs Market Share Analysis
The neonatal seizures drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neonatal seizures drugs market.
Some of the major players operating in the neonatal seizures drugs market are:
- Merck KGaA (Germany)
- Eisai Co., Ltd. (Japan)
- AstraZeneca (UK)
- Sanofi (France)
- Novartis AG (Switzerland)
- Abbott (US)
- Hoffmann-La Roche Ltd. (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- WOCKHARDT (Mumbai)
- Novo Nordisk A/S (Denmark)
- Glenmark Pharmaceuticals Limited (India)
- Cipla Inc. (US)
- Bausch Health Companies Inc. (Canada)
- Otsuka America Pharmaceutical, Inc. (US)
- Johnson Johnson Private Limited (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Sumitomo Corporation (Japan)
- Biocon (India)
Browse in-depth Research Report:- https://www.databridgemarketresearch.com/reports/global-neonatal-seizures-drugs-market
Top Related Reports: -
https://www.databridgemarketresearch.com/reports/global-veterinary-ivf-market
https://www.databridgemarketresearch.com/reports/global-endotracheal-and-tracheostomy-tube-market
https://www.databridgemarketresearch.com/reports/global-polycystic-ovary-syndrome-market
https://www.databridgemarketresearch.com/reports/global-calcineurin-inhibitors-market
About us: -
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in pune.
Data bridge market research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and ha bridge market research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact us: -
Data bridge market research
us: +1 888 387 2818
Email: - corporatesales@databridgemarketresearch.com
